`
`LINGUAL
`
`CROSSLINGUAL, LLC
`3736 Fallon Road, Suite 226
`Dublin, CA 94568
`Tel : 206-851-7932
`hr@clingual.com
`
`AFFIDAVIT OF TRANSLATION
`
`I, Alan F. Siegrist, of CROSSLINGUAL, LLC, hereby declare that:
`1.
`I am fluent in Japanese and English.
`2.
`I am an active member of the American Translators Association and a Certified
`Translator of Japanese to English.
`3. The English translation attached to this declaration is an accurate and correct
`translation of the following document, attached hereto:
`2002.6 - 2nd Edition [Bronuck Package Insert]
`I declare that the foregoing is true and correct to the best of my knowledge.
`
`Executed on October 29, 2015
`
`Alan F. Siegrist, CT
`CROSSLINGUAL, LLC
`ATA Member Nv. 31889
`Certification #63788
`
`Veity at WWN.atanel.or!Yferiy
`
`A notary public or other officer completing this certificate verifies only the identity of the individual who signed the
`documents to which this certificate are attached, and not the truthfulness, accuracy, or validity of that document.
`
`on Oc,.\t,~ 2,1 Jo \S
`• ~ 1
`State of California, County of ~-\-r,._ Cos~/
`1 . [ . 1
`before me,:Sote~ve-\l~e.- UL I ler ]doJ d1 ~
`personally appeared a1q11 r S·Rf1r\ s t
`
`who proved to me on the basis of satisfactory
`evidence to be the person whose name is subscribed to the within instrument and acknowledged to me
`that he executed the same in his authorized capacity, and that by his signature on the instrument the
`person, or the entity upon behalf of which the person acted, executed the instrument.
`
`I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
`paragraph is true and correct.
`
`Page 1 of 5
`
`SENJU EXHIBIT 2112
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`* June 2002 – Revised (Second Edition)
` May 2000 – Created
`Storage Method: Room temperature storage
`Expiration:
`To be used by the expiration date displayed on the exterior package
`(even before expiration, to be used promptly after opening).
`
`Japan Standard Commodity Classification No. 871319
`Approval No.
`21200AMZ00168
`Drug price listed
`May 2000
`Sales initiation
`July 2000
`International origin
`July 1997
`
`
`
`Non-steroidal anti-inflammatory ophthalmic agent
`Designated Prescription Drug BRONUCK® OPHTHALMIC SOLUTION
`Bromfenac sodium hydrate ophthalmic solution
`
`
`
`
`
`The following adverse effects were observed in the foregoing
`study.
`0.1% to less than 5%
`
`Ocular† Blepharitis, conjunctival hyperemia, stinging, ocular pain
`(temporary), corneal inflammation, corneal epithelial abrasion,
`superficial punctate keratitis, follicular conjunctivitis, pruritus,
`and burning sensation (eyelids)
`†When manifested, administration is suspended.
`3. Administration to Pregnant, Parturient, and Nursing
`Women
`Administration is to be conducted to pregnant woman or
`women who may have conceived and to women who are
`nursing only when it is judged that the benefits of treatment
`outweigh the risks.
`(The safety of administration during pregnancy and lactation
`has not been established.)
`4. Administration to Children
`Safety relative to children has not been established (there is
`little experience with use).
`5. Cautions for Use
`(1) Administration route: only to be used for ocular instillation
`(2) At time of administration: during ocular instillation, take
`care so that the lip of the container does not directly contact
`the eye.
`[Pharmacokinetics]
`(Reference)
`Intraocular Migration <rabbits>1)
`In testing wherein ocular instillation of 0.05 mL of 0.1% 14C-
`bromfenac sodium hydrate ophthalmic solution was conducted
`once a day is both eyes of rabbits, and radioactivity was
`measured after 15 minutes, 30 minutes, and 1, 2, 4, 8, 32, 24,
`48, and 72 hours, elevated values were observed in the cornea,
`conjunctiva, and anterior sclera.
`At 72 hours after ocular instillation, all ocular tissue except
`for the lens was below the detection limit (0.1 ng eq./g or ml).
`
`Cornea
`Conjunctiva
`Anterior sclera
`Anterior vitreous humor
`Blood
`Below detection limit
`
`Hours after ocular instillation
`
`(hours)
`
`
`Bromfenac sodium hydrate concentration
`
`
`
`[Contraindications (do not administer to the following
`patients)]
`Patients with a previous history of hypersensitivity to the
`ingredients of this drug
`[Composition / Properties]*
`Ingredients / content
`Bromfenac sodium hydrate 1 mg
`(in 1 ml)
`Boric acid, borax, dry sodium sulfite, sodium
`edetate, povidone, polysorbate 80,
`benzalkonium chloride, sodium hydroxide
`Aqueous ophthalmic solution
`Clear yellow
`8.0–8.6
`Aseptic preparation
`
`*Additives
`
`Form of drug
`Color
`pH
`Other
`[Efficacy / Effects]
`Symptomatic treatment of inflammatory ailments of the
`external eye and anterior eye (blepharitis, conjunctivitis,
`scleritis
`(including
`episcleritis),
`and
`postoperative
`inflammation)
`[Usage / Dosage]
`Ordinarily, 1-2 drops per administration, and 2 ocular
`instillations per day.
`[Cautions for Use]
`1. Important Basic Cautions
`(1) Keeping in mind that treatment by this drug is symptomatic
`treatment rather than causal treatment, and that it is
`reported that serious liver damage (including death) has
`been observed
`in patients subjected
`to
`long-term
`administration of 1 month or more with the oral agent of
`bromfenac sodium, continuous administration for 4 weeks
`or more is not conducted in principle. Although the
`aforementioned adverse effects observed with the foreign
`oral agent were due to long-term administration exceeding
`the approved usage and dosage, sales have been voluntarily
`suspended.
`(2) As there is risk that eye infection may become subclinical,
`in case of use on inflammation resulting from infection,
`administration is to be conducted carefully with adequate
`observation.
`2. Adverse Effects
`At the time of approval, adverse effects had been observed in
`16 out of a total of 423 cases (3.78%).
`With respect to the content of adverse effects, there were
`3 cases of blepharitis (0.71%), 3 cases of conjunctival
`hyperemia (0.71%), 3 cases of stinging (0.71%), 3 cases of
`ocular pain
`(temporary)
`(0.71%), 2 cases of corneal
`inflammation (0.47%), 1 case of conical epithelial abrasion
`(0.24%), 1 case of superficial punctate keratitis (0.24%), 1 case
`of follicular conjunctivitis (0.24%), 1 case of pruritus (0.24%),
`and l case of burning sensation (eyelids) (0.24%) (at the time of
`approval).
`
`Page 2 of 5
`
`
`
`[Principal Literature]
`1) Mitsuyoshi Isaka et al.: Pharmacokinetics, 14 (1) 32, 1999.
`2) Takahiro Ogawa et al.: Journal of Japan Ophthalmology Society, 99, 406, 1995.
`[Contact for Requesting Literature]
`Scientific Information Department
`Senju Pharmaceutical Co., Ltd.
`5-8, Hirano-machi 2-chome, Chuo-ku, Osaka-shi, Osaka
`
`Marketed by: Takeda Pharmaceutical Co., Ltd.
`
`1-1, Dosho-machi 4-chome,
`
`Chuo-ku, Osaka
`
`Package 02-075
`
`
`
`
`
`
`
`
`
`Efficacy rate (%) and
`effectiveness
`66.7 (6/9)
`63.2 (60/95)
`63.6 (7/11)
`86.4 (152/176)
`77.3 (225/291)
`
`relative
`
`to
`
`experimental
`
`[Clinical Results]
`A summary of results with respect to 291 cases including
`double-blind comparative testing are shown in the table.
`For the most part, daily dosage and administration period
`were 1 drop per administration and 2 administrations per day
`over a 2-week period.
`Table. Clinical Effects by Ailment
`Name of ailment
`Blepharitis
`Conjunctivitis
`Scleritis (including episcleritis)
`Postoperative inflammation
`Total
`[Pharmacoefficacy and Pharmacology]
`1. Pharmacological Action
`(1) Anti-inflammatory
`action
`conjunctival chemosis in rats2)
`It was observed that Bronuck ophthalmic solution exhibited
`anti-inflammatory action relative to experimental acute
`conjunctival chemosis in rats induced by arachidonic acid
`and carageenin.
`(2) Inhibitory effects relative to increases in aqueous humor
`protein concentration in rabbits after anterior chamber
`paracentesis or after laser irradiation2)
`It was observed that Bronuck ophthalmic solution almost
`completely inhibited increases in aqueous humor protein
`concentration in rabbits after anterior chamber paracentesis
`or after laser irradiation.
`2. Mechanism of Action
`In tests using rabbit iris-ciliary bodies2) and bovine seminal
`vesicles, it was confirmed that inhibitory action was exhibited
`against production of prostaglandin inflammatory mediators via
`cyclooxygenase (in vitro).
`[Physicochemical Findings Relative to Active Ingredients]
`Generic name:
`Bromfenac Sodium Hydrate (JAN)
`Chemical name:
`sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate sesquihydrate
`Molecular formula: C15H11BrNNaO3 · 1½ H2O
`Molecular weight: 383.17
`Structural formula:
`
`
`Properties:
`
`
`
`
`Bromfenac Sodium Hydrate is an odorless
`crystalline powder of yellow-orange color.
`It is freely soluble in water, soluble in
`methanol, slightly soluble in ethanol
`anhydride, and practically insoluble in
`acetonitrile or ether.
`
`[Packaging]
`5 mL × 10, 5 mL × 50
`
`
`
` Manufactured by: Senju Pharmaceutical Co., Ltd.
`
`
`5-8, Hirano-machi 2-chome,
`
`
`Chuo-ku, Osaka
`
`Page 3 of 5
`
`
`
`* 2002~ 6 JJ an(~ 2 !lti)
`2000~ 5 JJ t'FJ£
`
`liT ~ : *~**
`1li!JTIWlfl.R : ~f~n::il<:if-o:>1li!JTIJUJfl.RJ'-H::11J!JIIT J.>.:. t (1li!J1Ut1Jfl.RP-J<:
`c!;-::> -r <b,
`IJ~J1-HHti3!-?;N::1il!fflT J.>.::. t) o
`
`~~:A 7 D -1' ~'lim~HiE.Ii?.m~J
`fet)E~~~ "J"Ilt-·!1?£~~
`
`BRONUCK~OPHTHALMIC SOLUTION
`-:J'Db.7IT?T 1--IJ?b. 7..1<W~ .BOH~
`
`*~111'% 21200AMZ00168
`20001F 5 JJ
`~filfil!X~
`20001F 7 JJ
`~nrmt.rfl
`1997~ 7 JJ
`OO~i'.!~
`
`--
`
`[~~G~O):!~I;:I~~~l.J~lt't:c)l
`*M~-~~MLAa~~•tt•~~~m•
`
`r!Ht ·15:lll:
`(1 mL!fl)
`
`* i!:1Jn~
`
`:to A 7 :r. 7 7 7 1- 1J '7 A ll<fU~ lmg
`
`*'7~. *'7??P. ~~!IIHiil~trr •; '7A, :r...:r
`rm-rr~t'JA.~~~~.~~Y~~-J-8~
`tlHt~ ~ o!fJv::J.=.t';A, 7J<ifi1tt" 1- 1) t'JA
`
`~J %
`
`ll<f..l:l~IIR~J
`
`~
`
`pH
`
`-fo:>1&
`
`:t/I{Si_Qij}]
`
`8.0-8.6
`
`1!!1ili~~J
`
`[~fig.~~]
`
`~~B&UM~B~~~tt•m~M~a~C~~~.M~
`~. %!~~ U:Jnllf$'1;~ or 7;-tr). .uu~~~J
`[.E¥lj! • m•l
`D~. 1~1-2M. 182~~m~~ o
`
`[@!,Ef]_tO)j,t§]
`
`l..JI~t.J:¥:$:tt-.l5i:.
`(l l*~J ~: J: ~ maiJ:IJRINm~'t"li 7j: < M~1tt~"C'ili> ~
`.::.ti:W/;t;:i:L. it.:. :$'~1!)1:;J31t'"'C, '/OA7~-T
`~7~0~A~&DMorl~~~~-Mtt~L~m
`• ~:11J~ 7j: nff!I.Il!F C9Et: or-5-tr) i/{~~ e:, nt.:: t ~¥II
`~~~~~'t".M~tL"'C4~~~~~~~&~~
`~'Tb 7j: ~,-,.::. t o 7j: .to. :$'~00 ~-D~H: f&.~ '? ttt.::~
`2~•~m~*a~m~·m~or•~~*•&~~
`J: ~ t ~'t"~ ~ il~. 13 ±.I¥.J~:.ltOC?'Gor ~I•.LI:. L "'Cit' ~ o
`( 2 )1ll~!~W!~ or :;p~~JtfHt~ ~.to ~nil{~~~ 't". ~!41!
`1: J: ~~~~=M L "'C ffl~t' ~t,grg-1: IJ:Wl~or-t~~=~=r
`It', f:j'!jJ!~;:&~-~ ~.::.t o
`2. itlf1=Jl.l
`*~lli¥'"C'~~~f91J423f91Jr:p 16f91J (3.78%) l:liiU{'Fffl ;(){~~
`'?nt.::o
`/JIH'Ffflj1g~li, IIRI~~ 3 f~ (0.71%), MJ~.1ClfiL 3 f~ (0.71
`%). ~iU~!~3f~(0.71%). IIJHii[-AttJ 3111:(0.71%). ftJ
`~-~ 2fH0.47%). jtjJ~~.&:~IJ~ 1 fq:(0.24%). ~;jj(~
`}l]filil~ lf~(0.24%). -~illll?! lf~(0.24%). ml$~ 1
`f~(0.24%), ~~[IIR~J 1 f~(0.24%) 't"ib-? t.:: <*~-Wi) o
`
`0.1-5%*~
`DR tt> ~~~. *fil~:fC.lfiL. JPU~~. lll~ifi[ - ~ttJ.
`jfj~-11. fiJ)~~.&:~J~. ..~ ;jj( ~)\vi ftl il
`~ ' -~?&{Jif!!.. ml$~. i'&~ [IIRI~]
`?.±)36~ Lt.:: :Wi-g.~: li. r;:~- or r:p.LI:.~ ~.::.to
`3. ~~. I'm~. ~~L~~"(J)~~
`t~Hid JUJ:Rf~ L "'Cit'~ 11Jfmtt~~ ~~A&Ua;~r:p~
`~f} A~= li rum~ <7) ;ff :t,ttt il{fff.lfoitt or~ 1m ~ t :J!IJ mr ~ n
`
`~:t)}j-g.I:~J;.flt~~ ~.::.t o
`[Rf~r:p & ua:!fl~r ~!9:.!ij. ~= oo~ ~ '.tc~ttlifrtu: L "'( ~,,
`lj:lt'o]
`4. Jj\~'C~A.(J)~~
`tHM~~:M~ ~'.te~t'.tlift{OL. L "'Cit'lj: It' (fll!ffi*!~il{11
`lj:lt') o
`
`5.l!Jl.IJ::(J)5i:~
`(1 )~~*!~!: J~IIJUJH:~JJ.fll!ffl~ ~.::.t o
`(2)~ ~ ~ : ~~IR~ C: ~, ~~~5\;Y/Mil{fH:~ El ':fg]kn
`7j: ~,-, J: 1 ~=r±AJ.~ ~.::. e: o
`
`(~ ~)
`
`'7 "t.:¥o:>Jitiill!H::0.1%"C-:to A 7 :r. 77 T 1- 1J '7 A 7!<fU4m #.:IIRi!l
`0.05mL~ 1 l!il.r;':l;!IR !..-, 15, 307./', 1. 2. 4. 8, 12. 24. 48. 721~
`w•~atimft~a~~..-~~~~:~.~•·••&u•n••~
`l:HJli ~:iF !..- t..: o
`
`#.:I Ill. 7211HJI <: IJ:, * 1liH'" ~ ~1: < i"" _..z -r o:> ll!UJ.l fi'& <: ~ H:1 Ill W
`
`(O.lng eq./g or mL) .1.11.''fl:c!;-::> t..:o
`
`(ng eq./g or ml )
`10•
`
`- : ~ IIJ(
`o---o : fa
`IIJ(
`-
`: Ji'a&!!l!lilllt
`o---o: Jia)jiJ]j<
`............. : 1ln
`iili
`\\\\\\\\\ : l'litlli!BWL:rF
`
`0.1
`0
`
`\~~\\\~~\\\\\\\\\\~~\\\\\\\\\\\\\\\\\\\\\~
`1 2
`4
`8
`~~~~·~Ril
`
`12
`
`Page 4 of 5
`
`
`
`[Jlii);l<JiK:~]
`'=ll!lli'~l:t!l!l<MJRll>tJ~g; >l:ktr291 001:-:> <' -c (/) JlHollllU!f l:i3\<(J) 1:
`;13 ~ "t'<b.'.>o
`t.;:;/3, 1 BJlt.!j-:!1!:, Jlt.!j.J!Ilr.IH:i:kllll:lf~< 11!!11 illj, 1 B 21!!1, 23!'1
`r.!l"t'<b.'.>o
`*· ~.!!!,gijlliJil<~*
`~.II!. ,g
`
`;ff~$ (%) ;ff~W.J:
`
`llllii&JI<
`>llillllll<
`'lllllllll<
`(J:'ll!llll~>l:ktr)
`
`'it:ill!JI<IiE
`ot
`1r
`
`. -
`
`66.7 ( 61 9)
`
`.·.
`
`63.2 ( 60/ 95)
`
`.
`
`63.6 ( 71 ll)
`
`86.4 (152/176)
`
`77.3 (225/291)
`
`[ili!liihllillJm l
`1.lll!!11!f'i'Jll
`. '
`(1 )':h ~~Mifl'l~lll!i!J!JII:Mi" ?.>ttJJi:liEf'FJll"
`~a~,~~llll8~,,~~;13~.<,j,•p~~, *'¥:
`~ l: J: .'.> ~Mifi'J%!ft>llfllllj!J!J!IH:Mt..-IJtll<liEf'i'Jll >l:ff-T: 1: ~'
`•.Jil.t!bG;!J,"C<>.'.>o
`( 2 I? oft ~iifi);il!';Jllfl!:l!.l;t v - if -!lllf1il! 0) B!:>f< lli s il.ll!:Jtl~n 1:
`Mi" 7.>j!)Jf!;!J;(b*''
`. ~a~,~ ~llll81:i7"'i"'l'l:cl31t .'.> lilfl>Hl•;J!JiitJU:i v-;--lf(cid:173)
`IR!Miit(J)!ij7]<l!<E!il!t!lt!i!!tn >;; l:!l>t%~1:j!JJIIJJT "-': 1: i.>'lil.t!b
`G;!J, "C<>.'.>o
`2. f'F Jlllli!fi'; .
`. 7 "'i"'I'!I!Cl!ft'li$lHt<'11>l.V'7 'l:ml!li>l: ill<' to:lit~jg;l:cl3<'-c, ,_, ~
`a~·'l¥~-~>;;ftT.'.>~UA7~,~9~*(J)jl<li£~r1
`:r.- 7 -tf.JJ<j!)J~~fj;Jil >l:ff-T: 1: i.><l1Jtiill ~ ;11, -c ''.'.>(in vitro);
`
`[~iiJJRK::SJ-1<:: 009 :QJI1~!'¥~9<11Jl] .
`-IJlt:l'.: ~UA7oo~~~ ~ 1) ?A 7)<1'1J'itJ
`(Bromfenac Sodium Hydrate) (JAN)
`{~~~:sodium 2-amino-3-(4-bromobenzoyl)phenylacetate
`sesquihydrate
`:7}-=f:A; : CtsHuBrNNa03 · 1 t H20
`:lt'f:!i!: : 383.17
`IU"': Br~~-Q
`
`H2N
`
`CH2C02Na • 1I12H20
`
`ft ;fi(: ~UA 7 oo~7~ ~ >J ?A 7)<1'1J'itJI:i, 'P\:f!l-jllf!l(J)Ii'f,ll,
`ft(/):llf*'-', 1:;13 <> l:i iJ:<'o
`7l<l:il"flt~TC ~ 7 /-!vl:~~il"flt~-J-<, :f!!\7J<:r.
`7/ -Jvl:il"fltl: < <- 7-l! ~: ~ 'J !v Xl:i:r.-7" !VI:
`1:! /: /v /:"il"fltfJ:<>o
`
`["2!
`. ~]
`5mLX10, 5mLX50
`
`[:E~:stii!:l
`1) #f!(J'i;Jill!! : lll!'itl!llJJiili. 14(1). 32. 1999.
`2) 'NiiJ:Ilt11il!! : B *lllll'f'lt~llti\5. 99. 406. 1995.
`l'li
`
`[ )l:ifi!:i~>.I<S'c l '
`'flll'lllllll!<*"'~*± 'ltlfitll*l!llll
`'i'54H046. {':llllm<P91:JR'I"!I!fPIT=TI'I5lli'8.jJ-
`
`..
`
`,_- :
`
`'
`
`(
`
`'
`
`~02-075
`
`Page 5 of 5